Important Considerations in the Diagnosis and Management of Post-transplant Lymphoproliferative Disorder
Authors:
- 10 May 2023
- journal article
- review article
- Published by Springer Nature in Current Oncology Reports
- Vol. 25 (8) , 883-895
Abstract
Purpose of Review A relative lack of molecular and clinical studies compared to other lymphoid cancers has historically made it difficult to determine optimal management approaches in post-transplant lymphoproliferative disorder (PTLD). We sought to better define the “state of the science” in PTLD by examining recent advances in risk assessment, genomic profiling, and trials of PTLD-directed therapy. Recent Findings Several major clinical trials highlight risk-stratified sequential therapy incorporating rituximab with or without chemotherapy as a rational treatment strategy in patients with CD20+ PTLD who do not respond to reduction of immunosuppression alone. Epstein Barr virus (EBV)-targeted cytotoxic lymphocytes are a promising approach in patients with relapsed/refractory EBV+ PTLD, but dedicated clinical trials should determine how autologous chimeric antigen receptor T cell therapy (CAR-T) may be safely administered to PTLD patients. Summary Sequencing studies underscore the important effect of EBV infection on PTLD pathogenesis, but comprehensive genomic and tumor microenvironment profiling are needed to identify biomarkers that predict response to treatment in this clinically heterogeneous disease.Keywords
Funding Information
- Lymphoma Research Foundation (611735)
- National Cancer Institute (1R01CA266052)
This publication has 102 references indexed in Scilit:
- Epstein–Barr Virus Infection and Posttransplant Lymphoproliferative DisorderAmerican Journal of Transplantation, 2013
- Early Posttransplant Lymphoproliferative DiseaseAmerican Journal of Clinical Pathology, 2012
- Spectrum of Cancer Risk Among US Solid Organ Transplant RecipientsJAMA, 2011
- Reduction of Immunosuppression as Initial Therapy for Posttransplantation Lymphoproliferative Disorder★American Journal of Transplantation, 2011
- Risk factors for early‐onset and late‐onset post‐transplant lymphoproliferative disorder in kidney recipients in the United StatesAmerican Journal of Hematology, 2010
- Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global PerspectiveTransplantation and Cellular Therapy, 2009
- Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantationBlood, 2009
- Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative diseaseHaematologica, 2007
- Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantationCancer, 2005
- Epstein-Barr virus: exploiting the immune systemNature Reviews Immunology, 2001